LCN2 and Alzheimer disease: ELISA measurements showed that serum LCN2 concentrations were significantly higher in patients with psoriasis (80.08 ± 51.3 ng/ml) and AD (78.32 ± 43.42 ng/ml) than those in healthy controls (59.07 ± 20.18 ng/ml, P < 0.05 each), but there was no significant deference in serum LCN2 levels between psoriasis and AD patients (Figure 1).